Mobile

A PHASE 2A, DOUBLE BLIND (3RD PARTY OPEN), 4 WAY CROSS-OVER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, TOLERATION AND EFFICACY OF SINGLE INHALED DOSES OF PF-00610355 IN MOD...

Update Il y a 4 ans
Reference: EUCTR2008-001396-30

A PHASE 2A, DOUBLE BLIND (3RD PARTY OPEN), 4 WAY CROSS-OVER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, TOLERATION AND EFFICACY OF SINGLE INHALED DOSES OF PF-00610355 IN MODERATE COPD PATIENTS

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

• To characterize the single dose pharmacokinetics of inhaled PF-00610355 in COPD patients. • To evaluate the safety & toleration of single inhaled doses of PF-00610355 in COPD patients.

Inclusion criteria

  • Chronic Obstructive Pulmonary Disease (COPD)

Links